Drug intelligence / Profile preview

StabiliC

Development stage: Preclinical
Lead developer: NeuroSense Therapeutics
Modality: Small Molecules

Overview

StabiliC is a small molecule drug developed by Neurosense Therapeutics. It functions as a cyclooxygenase-2 (COX-2) inhibitor, targeting the COX-2 enzyme to reduce inflammation. The primary therapeutic focus for StabiliC is in the treatment of nervous system diseases, with Parkinson's disease being its main active indication. As of May 2025, the drug remains in preclinical development and has not yet advanced to clinical trials or received regulatory approval[2].

Brand names: StabiliC

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on StabiliC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StabiliC.

Explore the full profile